Prevention Of Venous Thrombo Embolism After Joint Replacement Surgery By Rivaroxaban, Fondaparinux Sodium, And Enoxaparin:a Retrospective Study

Objectives:To evaluate the clinical effects and the security of rivaroxaban, fondaparinux sodium and enoxaparin for the prevention of venous thrombo embolism (VTE) after joint replacement surgery.Methods:The clinical data of253patients receiving joint replacement, between January2010-December2012, was retrospectively analyzed. The incidence of VTE and bleeding complications during hospitalization were evaluated.Results:1) There were no statistical differences in the gender, age, height, weight, disease duration and type of surgery in the three groups (P>0.05).2) A total of14patients were found to suffer postoperative VTE (5.5%). The incidence of VTE was5.7%in rivaroxaban group,5.7%in fondaparinux sodium group, and5.1%in enoxaparin group. There were no significant differences in these three groups (P>0.05).3) The incidence of bleeding had no statistical difference in the three groups (P>0.05). The level of hemoglobin and platelet counts had no statistical differences in the three groups (P>0.05).Conclusions:The clinical effects and security of rivaroxaban, fondaparinux sodium and enoxaparin have no obvious statistical differences for the prevention of VTE aftert joint replacement surgery.